semaglutide versus glp-1 & tirzepatide are transforming diabetes & obesity management. These receptor agonists offer benefits from glycemic control to weight loss and cardiovascular risk reduction, emphasizing their broad impact. Read more from File:Tirzepatide+Semaglutide vs. GLP-1 GIP.svg -

In a randomized trial of semaglutide 2.4 mg vs placebo for 1 year, 529 participants with HFpEF with a BMI of 30 kg/m2, there was a very large reduction in symptoms, improvement in exercise function in the GLP-1 drug assigned group

Side Effects: Rare (mild digestive upset at high doses)

Adults with SPCD must still avoid prolonged fastingwhich generally means skipping meals during the day, fasting for religious reasons, or fasting prior to medical procedures/bloodworkand must take their prescribed L-carnitine consistently to avoid muscle breakdown ( rhabdomyolysis ) and other complications [10] [6]

& Luiten, P

sitagliptin once daily on 24-hour acute glucose fluctuations

Neumiller JJ, Sonnett TE, Wood LD, et al